scholarly journals DNA methylation profiles capturing breast cancer heterogeneity

BMC Genomics ◽  
2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Xiao Chen ◽  
Jianying Zhang ◽  
Xiaofeng Dai
Keyword(s):  
Breast Cancer ◽  
Dna Methylation ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Gene Expression Regulation ◽  
Breast Cancer Subtype ◽  
Breast Cancer Prognosis ◽  
Cancer Prognosis ◽  
Cancer Subtypes ◽  
Cancer Heterogeneity

Abstract Background As one of the most described epigenetic marks in human cancers, DNA methylation plays essential roles in gene expression regulation and has been implicated in the prognosis and therapeutics of many cancers. We are motivated in this study to explore DNA methylation profiles capturing breast cancer heterogeneity to improve breast cancer prognosis at the epigenetic level. Results Through comparisons on differentially methylated CpG sites among breast cancer subtypes followed by a sequential validation and functional studies using computational approaches, we propose 313 CpG, corresponding to 191 genes, whose methylation pattern identifies the triple negative breast cancer subtype, and report cell migration as represented by extracellular matrix organization and cell proliferation as mediated via MAPK and Wnt signalings are the primary factors driving breast cancer subtyping. Conclusions Our study offers novel CpGs and gene methylation patterns with translational potential on triple negative breast cancer prognosis, as well as fresh insights from the epigenetic level on breast cancer heterogeneity.

Epigenetic aspects of triple-negative in patients with breast cancer.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 1041-1041
Author(s):  
Joaquina Martínez-Galan ◽  
Sandra Rios ◽  
Juan Ramon Delgado ◽  
Blanca Torres-Torres ◽  
Jesus Lopez-Peñalver ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Dna Methylation ◽  
Triple Negative ◽  
Breast Cancer Subtype ◽  
Regulation Of Gene Expression ◽  
Breast Cancer Subtypes ◽  
Luminal A ◽  
Cancer Subtypes ◽  
Luminal B

1041 Background: Identification of gene expression-based breast cancer subtypes is considered a critical means of prognostication. Genetic mutations along with epigenetic alterations contribute to gene-expression changes occurring in breast cancer. However, the reproducibility of differential DNA methylation discoveries for cancer and the relationship between DNA methylation and aberrant gene expression have not been systematically analysed. The present study was undertaken to dissect the breast cancer methylome and to deliver specific epigenotypes associated with particular breast cancer subtypes. Methods: By using Real Time QMSPCR SYBR green we analyzed DNA methylation in regulatory regions of 107 pts with breast cancer and analyzed association with prognostics factor in triple negative breast cancer and methylation promoter ESR1, APC, E-Cadherin, Rar B and 14-3-3 sigma. Results: We identified novel subtype-specific epigenotypes that clearly demonstrate the differences in the methylation profiles of basal-like and human epidermal growth factor 2 (HER2)-overexpressing tumors. Of the cases, 37pts (40%) were Luminal A (LA), 32pts (33%) Luminal B (LB), 14pts (15%) Triple-negative (TN), and 9pts (10%) HER2+. DNA hypermethylation was highly inversely correlated with the down-regulation of gene expression. Methylation of this panel of promoter was found more frequently in triple negative and HER2 phenotype. ESR1 was preferably associated with TN(80%) and HER2+(60%) subtype. With a median follow up of 6 years, we found worse overall survival (OS) with more frequent ESR1 methylation gene(p>0.05), Luminal A;ESR1 Methylation OS at 5 years 81% vs 93% when was ESR1 Unmethylation. Luminal B;ESR1 Methylation 86% SG at 5 years vs 92% in Unmethylation ESR1. Triple negative;ESR1 Methylation SG at 5 years 75% vs 80% in unmethylation ESR1. HER2;ESR1 Methylation SG at 5 years was 66.7% vs 75% in unmethylation ESR1. Conclusions: Our results provide evidence that well-defined DNA methylation profiles enable breast cancer subtype prediction and support the utilization of this biomarker for prognostication and therapeutic stratification of patients with breast cancer.

scholarly journals Correlation of L-type amino acid transporter 1 and CD98 expression with triple negative breast cancer prognosis

2011 ◽  
Vol 103 (2) ◽  
pp. 382-389 ◽  
Author(s):  
Mio Furuya ◽  
Jun Horiguchi ◽  
Hiroki Nakajima ◽  
Yoshikatsu Kanai ◽  
Tetsunari Oyama
Keyword(s):  
Breast Cancer ◽  
Amino Acid ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Amino Acid Transporter ◽  
Breast Cancer Prognosis ◽  
Cancer Prognosis ◽  
Acid Transporter

The relationship between body mass index, diabetes, and triple-negative breast cancer prognosis.

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 1108-1108
Author(s):  
Jose Maria Pacheco ◽  
Sarah Tait ◽  
Feng Gao ◽  
Caroline Bumb ◽  
Matthew James Ellis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Body Mass Index ◽  
Body Mass ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Breast Cancer Prognosis ◽  
Cancer Prognosis ◽  
The Relationship

Body mass index, diabetes, and triple-negative breast cancer prognosis

2014 ◽  
Vol 146 (1) ◽  
pp. 189-197 ◽  
Author(s):  
Sarah Tait ◽  
Jose M. Pacheco ◽  
Feng Gao ◽  
Caroline Bumb ◽  
Matthew James Ellis ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Body Mass Index ◽  
Body Mass ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Breast Cancer Prognosis ◽  
Cancer Prognosis
Sign in / Sign up

Export Citation Format

Share Document